type 2 diabetes, obesity and Tirzepatide

Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease, dyslipidaemia, hypertension, obstructive or sleep apnoea (OSA).
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes
Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.
Tirzepatide Demonstrates Long-Term Weight Reduction and Diabetes Risk Reduction in Obesity and Prediabetes: NEJM
Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a previous analysis of the SURMOUNT-1 trial, tirzepatide pro
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drug | In the three-year SURMOUNT-1 trial,
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new results from a three-year trial.
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide - the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated.
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Comedian Jim Gaffigan says he lost 50 pounds on Mounjaro
Gaffigan admitted to having trepidation to use the medication, a brand name for tirzepatide, after tipping the scales at 270 ...
What to know about the risks of using weight loss drugs unsupervised
The use of weight loss drugs without doctor's supervision is not advisable and can lead to serious side effects and ...
Monthly Prescribing Reference23h
Long-Term Tirzepatide Treatment Reduces Weight and Diabetes Progression Risk
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
tyla3d
Company behind weight loss drug Mounjaro issues statement as first Brit dies after using jab twice
Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Global increase in diabetes indicates more room for GLP-1 meds to grow
A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...
Becker's Hospital Review1d
Mounjaro lowers Type 2 diabetes risk in phase 3 trial: Study
A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...
kffhealthnews1d
Semaglutide Appears To Aid People With Alcohol Use Disorder, Study Says
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.